872 - Comparative Efficacy of Sunitinib Versus Sorafenib as the First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma

Abstract

ABSTRACT Background Sunitinib has been recommended as the primary treatment in the patients with metastatic renal cell carcinoma (mRCC) among the vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI). However, there are no published clinical data that compared directly the efficacy of targeted agents in the first line setting. This study investigated the efficacy and toxicity of sorafenib and sunitinib as primary treatment for patients with mRCC. Methods To compare the efficacy and toxicities between sorafenib and sunitinb, clinical database was used to identify all patients with mRCC treated with VEGF TKIs in Asan Medical Center from April 2005 to March 2011. Among 304 patients, we identified 49 and 220 patients who were treated first with sorafenib and sunitinib, respectively. Results The patients in the sorafenib group were older than those in the sunitinib group (62 vs 56.5 years, p = 0.019). Disease control rate (DCR) of 71% and 74% were achieved in sorafenib and sunitinib groups, respectively (p = 0.687). After a median follow-up duration of 27.6 months, progression free survival (PFS), time to treatment failure (TTF), and overall survival (OS) were not significantly different between the groups (sorafenib vs. sunitinib, PFS 8.6 months vs. 9.9 months, p = 0.948; TTF 6.6 months vs. 7.2 months, p = 0.665; OS; 25.7 months vs. 22.6 months, p = 0.774). Patients treated with sorafenib required dose reduction due to toxicities less frequently than those treated with sunitinib (37% vs. 54%, p = 0.034). Haematological toxicities of grade 3 or 4 were more common in the sunitinib group than in the sorafenib group (45% vs. 4%, p 60 years), duration from diagnosis to treatment ( Conclusion Sorafenib showed comparable efficacy to sunitinb and demonstrated fewer and less severe toxicities in the treatment of mRCC patients. Disclosure All authors have declared no conflicts of interest.